Zobrazeno 1 - 10
of 186
pro vyhledávání: '"H G, Meerpohl"'
Autor:
Yan Xing, Ali Ayhan, Jonathan S. Berek, Jalid Sehouli, Wen Juan Tian, A. du Bois, H. Oksefjell, Christina Fotopoulou, Claes G. Tropé, G. P. Breitbach, Rongyu Zang, Dennis S. Chi, Elena-Ioana Braicu, Gennaro Cormio, Catherine Rabbitt, H. G. Meerpohl, P. Harter, Rong Jiang
Publikováno v:
Annals of Surgical Oncology. 19:597-604
To develop a risk model for predicting complete secondary cytoreductive surgery (SCR) in patients with recurrent ovarian cancer. Individual data of 1075 patients with recurrent ovarian cancer undergoing SCR from 7 worldwide centers were pooled and an
Autor:
Hans-Joachim Lück, Christoph Thomssen, Rolf Kreienberg, Alexey Manikhas, Christian Jackisch, Alexandra Coumbos, Volkmar Müller, Olivier Catalani, H. G. Meerpohl, Mikhail Lichinitser, M. Muscholl, Sergei Tjulandin, Walter Jonat, Michael Untch, Nadia Harbeck, Matthias Pauschinger, Michaela Lehle, Andreas du Bois
Publikováno v:
Journal of Clinical Oncology. 28:1473-1480
Purpose A high incidence of congestive heart failure (CHF) has been observed in patients with metastatic breast cancer (MBC) receiving doxorubicin-based chemotherapy and trastuzumab. The Herceptin, Cyclophosphamide, and Epirubicin (HERCULES) trial ev
Autor:
Daniel Fink, Philipp Harter, Jacobus Pfisterer, Jens Huober, M. Gropp, Jalid Sehouli, M. Hahmann, Karsten Muenstedt, Berno Tanner, Annette Hasenburg, Barbara Schmalfeldt, Alexander Burges, G. P. Breitbach, H. G. Meerpohl, Sibylle Loibl, K. Wollschlaeger, Guenter Emons, W. Schröder, Andreas du Bois
Publikováno v:
Annals of Surgical Oncology. 13:1702-1710
The role of cytoreductive surgery in relapsed ovarian cancer is not clearly defined. Therefore, patient selection remains arbitrary and depends on the center's preference rather than on established selection criteria. The Descriptive Evaluation of pr
Autor:
K Höffken, A Ebert, A. du Bois, Peter Reichardt, Diethelm Wallwiener, Günter Emons, H. G. Meerpohl, M. Muscholl, W Wiese, H.-J. Lück, M Pauschinger, V Heilman, Nadia Harbeck, J-U Blohmer, Michael Untch, C. Thomssen, Walther Kuhn, B Langer, Holger Eidtmann, C. Jackisch
Publikováno v:
European Journal of Cancer. 40:988-997
This prospective, parallel-group, dose-escalation study evaluated the cardiac safety of trastuzumab (Herceptin) plus epirubicin/cyclophosphamide (EC) in women with human epidermal growth factor receptor-2 (HER2)-positive metastatic breast cancer (MBC
Autor:
H. G. Meerpohl
Publikováno v:
Der Onkologe. 8:1187-1200
Publikováno v:
Der Gynäkologe. 34:1041-1049
Bei knapp 33% aller Patientinnen mit epithelialem Ovarialkarzinom wird die Diagnose bereits in einem fruhen Stadium mit lokoregionar begrenzter Tumorausbreitung gestellt. Die Abschatzung des Rezidivrisikos und der Chancen auf Langzeituberleben erfolg
Autor:
HJ Lück, Markus P. Schlaich, U Wechsel, A. du Bois, A Mollenkopf, M Rauchholz, Thomas Bauknecht, H. G. Meerpohl
Publikováno v:
Supportive Care in Cancer. 7:354-361
The most important cytotoxic drugs for the treatment of ovarian cancer, platinum compounds and paclitaxel, are known to induce neurotoxicity, which is dose limiting when higher paclitaxel doses are used or platinum-pretreated patients are treated. Th
Publikováno v:
Der Onkologe. 4:1096-1100
Autor:
H. G. Meerpohl, A. du Bois
Publikováno v:
Der Onkologe. 4:1131-1139
Autor:
H. Maier-Lenz, Klaus Mross, B. Hauns, Clemens Unger, Thomas Bauknecht, B. Häring, H. G. Meerpohl
Publikováno v:
Annals of Oncology. 9:569-572
Summary Background Paclitaxel (PAC) is one of the major anti-cancer drugs, effective in different tumors. Studies with 24-hour infusion with 135 mg/m2 and a three-hour infusion with 175 mg/m2 showed a significant schedule-dependent toxicity. We evalu